Canton Strategic Holdings (CNTN) Net Income towards Common Stockholders (2021 - 2026)
Canton Strategic Holdings (CNTN) posted Net Income towards Common Stockholders of -$47.3 million for Q1 2026, down 248.26% on a QoQ basis from -$13.6 million in Q4 2025, and down 1762.66% year-over-year from $2.8 million in Q1 2025.
Canton Strategic Holdings (CNTN) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Canton Strategic Holdings' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$47.3 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 1762.66% year-over-year to -$47.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$64.9 million (down 421.27% YoY) and the FY2025 annual result came in at -$42.9 million, down 252.06% from the prior year.
- Net Income towards Common Stockholders was -$47.3 million for Q1 2026 at Canton Strategic Holdings, down from -$13.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$188679.0 in Q4 2022 and bottomed at -$47.3 million in Q1 2026.
- A 5-year average of -$5.6 million and a median of -$2.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 47.53% — and 2026, when it sank 1762.66%.
- Canton Strategic Holdings' Net Income towards Common Stockholders stood at -$188679.0 in 2022, then sank by 1211.1% to -$2.5 million in 2023, then plunged by 53.08% to -$3.8 million in 2024, then tumbled by 259.0% to -$13.6 million in 2025, then slumped by 248.26% to -$47.3 million in 2026.
- Business Quant data shows CNTN's Net Income towards Common Stockholders at -$47.3 million in Q1 2026, -$13.6 million in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | -0.68 |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Canton Strategic Holdings | 426.84 Mn | 426.84 Mn | - | -47.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.34 Mn |
| Dec 31, 2025 | -13.59 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.86 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.79 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -188,679.00 |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -359,593.00 |
| Sep 30, 2021 | -777,113.00 |
| Jun 30, 2021 | -1.29 Mn |